Axon Enterprise (AXON) closed at $441.12 in the latest trading session, marking a +2.56% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.28%. Elsewhere, the Dow saw a downswing of 0.54%, while the tech-heavy Nasdaq depreciated by 0.31%. Shares of the maker of stun guns and body cameras witnessed a loss of 29.52% over the previous month, trailing the performance of the Aerospace sector with its loss of 2.29%, and the S&P 500's loss of 0.76%.The investment community wil ...

Group 1 - Axon Enterprise Inc (NASDAQ:AXON) is ranked third among top digital infrastructure and connectivity software companies, indicating strong growth potential in public safety technology [1] - The company is expected to benefit from new drone regulations, AI features, and its Officer Safety Plan, which enhances its recurring revenue model and long-term outlook [1] - The Department of Homeland Security's announcement to expand the use of body-worn cameras presents a significant opportunity for Axon, as many agencies lack sufficient cameras [3][4] Group 2 - William Blair has reaffirmed an Outperform rating on Axon, highlighting the potential increase in demand for its products due to the policy shift by the Department of Homeland Security [2][4] - Initial funding of $20 million for body-worn cameras is seen as just the beginning, with further growth expected through Axon's Evidence ecosystem, which includes cloud storage and digital tools [4] - Axon is a global provider of public safety technology solutions, including body-worn cameras for US law enforcement agencies, and was founded in 1993 [5]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Company Overview - Axon Enterprise (AXON) shares increased by 3% to $446.97 in the last trading session, following a significant volume of shares traded, despite a 31.3% loss over the past four weeks [1] Business Segments - The growth in Axon's stock is primarily attributed to the strong performance of its Connected Devices segment, driven by high demand for TASER devices, virtual reality training services, and counter-drone equipment [2] - The popularity of the next-generation TASER 10 products, which began shipping in 2023, is also contributing to the segment's growth [2] Financial Performance - Axon is expected to report quarterly earnings of $1.67 per share, reflecting a year-over-year decline of 19.7%, while revenues are projected to reach $753.65 million, marking a 31% increase from the same quarter last year [3] - The consensus EPS estimate for Axon has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Axon operates within the Zacks Aerospace - Defense Equipment industry, where another company, Airbus SE - Unsponsored ADR (EADSY), experienced a 1.4% decline in its last trading session and has returned -8.6% over the past month [4] - Airbus SE's consensus EPS estimate for its upcoming report is $0.88, representing a 7.3% increase from the previous year, with a Zacks Rank of 3 (Hold) [5]

Core Viewpoint - Software stocks have experienced a significant sell-off, but not all are considered good investment opportunities, with specific recommendations for buying and avoiding certain stocks [1][2]. Group 1: Axon Enterprise (Buy Recommendation) - Axon Enterprise has seen its stock decline approximately 50% from its peak six months ago and 25% from two weeks ago, making it a potential buy [4]. - The company combines hardware and software, creating a resilient ecosystem that retains customers, particularly law enforcement agencies, which are less likely to develop custom AI software [5][7]. - Axon is expected to grow rapidly, with projected revenue growth of 31% for 2025, reaching $2.74 billion, despite a high price-to-sales ratio of 14 [8]. Group 2: Atlassian (Avoid Recommendation) - Atlassian has a large customer base, including over 350,000 customers and 80% of the Fortune 500, but its stock has dropped 72% over the past year due to AI-related fears [9][10]. - The company reported a 23% revenue growth to $1.6 billion in the fiscal second quarter, but it has been GAAP unprofitable for the last 10 years, raising concerns about its long-term viability [10][14]. - Atlassian's products are seen as vulnerable to AI disruption, and the company has been heavily reliant on share-based compensation, which could dilute shareholder value [13][15].

Core Viewpoint - Axon is set to release its fourth quarter 2025 financial results on February 24, 2026, and will host a live webinar to discuss these results, highlighting its ongoing commitment to public safety technology innovation [1]. Upcoming Financial Events - The financial results will be reported after market close on February 24, 2026, followed by a live Zoom webinar at 4:30 p.m. ET, lasting 90 minutes, which will include a presentation and Q&A session [1]. - Axon will also participate in the Morgan Stanley Technology, Media & Telecom Conference on March 3, 2026, and the Bank of America Global Industrials Conference on March 19, 2026, with events available for live webcast and archived on its investor relations website [1]. Company Overview - Axon, founded in 1993, is a leader in public safety technology, focusing on innovative solutions for law enforcement and public safety [1]. - The company offers a comprehensive network of products, including TASER devices, cameras, drones, and AI-driven capabilities, aimed at enhancing safety and accountability [1]. - Axon emphasizes responsible innovation, ensuring that technology serves humanity and is developed in collaboration with users, guided by principles of transparency and accountability [1].

Group 1 - Axon Enterprise (AXON) is successfully providing utility-like SaaS infrastructure to government customers, indicating a shift in the nature of its business that investors are beginning to recognize [1] - The success of Axon may be changing the business dynamics in ways that the market is just starting to understand [1] Group 2 - Mr. Arunangshu Das is developing Tranzoro Investments to bridge the gap between US and Indian investors, focusing on liquid India-focused ETFs and ADRs for US investors while covering a wide range of US equities, ETFs, and REITs for Indian investors [1]

Core Insights - Fidelity Growth Strategies Fund's fourth-quarter 2025 investor letter indicates a focus on midcap growth stocks, emphasizing quality companies with steady above-average growth potential [1] - The Fund's Retail Class shares returned -3.44% in Q4 2025, outperforming the benchmark Russell Midcap® Growth Index, which returned -3.70% [1] - The U.S. stock market experienced a rebound driven by strong corporate fundamentals and significant spending on artificial intelligence, although mid-cap growth stocks underperformed [1] Company-Specific Insights - Axon Enterprise, Inc. (NASDAQ:AXON) was highlighted as a leading relative detractor for the Fidelity Growth Strategies Fund, with a stock price of $430.65 as of February 4, 2026 [2] - Axon delivered a -29.74% return in the past month and a -36.43% return over the past twelve months, with a market capitalization of $3.101 billion [2] - The Fund's larger-than-benchmark position in Axon (-21%) was the biggest detractor from relative performance, attributed to disappointing quarterly results where revenue exceeded forecasts but earnings fell short due to weaker margins [3]

Company Overview - Axon Enterprise, Inc. (NASDAQ:AXON) develops and sells TASER devices, body and fleet cameras, and software solutions for law enforcement to capture, store, and manage digital evidence [3]. Market Sentiment - Recent commentary from Jim Cramer indicated mixed sentiment regarding Axon stock, noting a recent increase in stock price due to a body camera story in Minnesota, but also a quick reversal of gains, suggesting the stock may be too heavy [1]. - Cramer advised investors to trim their positions in Axon, indicating that the stock is not performing well despite initial positive news [1]. Investment Perspective - While there is acknowledgment of Axon's potential as an investment, there is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to Axon [4].

Core Viewpoint - Baillie Gifford continues to focus on technology and growth sectors, maintaining a global perspective despite a reduction in total assets held to $120 billion, down $15 billion from the previous quarter [1]. Holdings Overview - As of Q4 2025, Baillie Gifford holds a total of 265 companies with assets amounting to $120 billion, reflecting a decrease of $15 billion from Q3 [1]. Top Holdings - The firm remains heavily invested in global technology and consumer giants, with a notable emphasis on Latin American e-commerce platform MercadoLibre, and Nvidia leading the portfolio, indicating confidence in the long-term potential of AI infrastructure [4]. Top Buys - Significant increases in holdings include: - Axon Enterprise (AXON) with an additional investment of $860 million - Medline Inc (MDLN) with $437 million - Rocket Lab (RKLB) with $399 million - Google-A (GOOGL) with $373 million - Duolingo (DUOL) with $357 million - The firm shows strong interest in vertical technology sectors, particularly in safety technology and education [5][6]. Top Sells - The firm has reduced its positions in: - Datadog Inc (DDOG) by $1.01 billion - Cloudflare (NET) by $990 million - Shopify (SHOP) by $680 million - BioNTech SE (BNTX) by $630 million - Meta Platforms (META) by $590 million - This indicates a strategic retreat from cloud computing and vaccine-related companies, likely based on valuation and growth switching logic [7][8]. New Positions - New investments include: - Medline Inc (MDLN) with $437 million - United Therapeutics (UTHR) with $157 million - MongoDB (MDB) with $112 million - BillionToOne (BLLN) with $104 million - Silvergate Capital (SVM) with $35 million - The new positions reflect Baillie Gifford's exploration in emerging fields such as rare disease treatment and databases, showcasing a commitment to long-term tracking in technology and healthcare [9][10].